Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441686 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 8
- Study locations
NCT02441686 is a Phase 2 study of Multiple Myeloma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 46 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT02441686, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- PROCEDURE Autologous Stem Cell Transplant
- PROCEDURE Stem Cell Mobilization
Study Locations (8)
Massachusetts
- Massachusetts General Hosptial - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Minnesota
- Virginia Piper Cancer Institute - Coon Rapids
- Virgina Piper Cancer Institute - Minneapolis
Colorado
- Colorado Blood Cancer Institute - Denver
Maine
- Eastern Maine Medical Center - Brewer
New Jersey
- Hematology Oncology of Northern New Jersey - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-12 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02441686
The ClinicalTrials.gov registry entry for NCT02441686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT02441686 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Minnesota, Colorado.
Frequently Asked Questions
What is clinical trial NCT02441686 about?
NCT02441686 is a clinical study titled "Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma". This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
What is the current status of trial NCT02441686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-12. Estimated completion is 2025-10.
What conditions does trial NCT02441686 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02441686?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Autologous Stem Cell Transplant (PROCEDURE), Stem Cell Mobilization (PROCEDURE).
Who is sponsoring clinical trial NCT02441686?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02441686 being conducted?
This trial has 8 study locations across Colorado, Maine, Massachusetts, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.